Entering the era of agentic AI will shift investment to agentic experiences, but keeping humans at the center of the customer ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

Artificial intelligence (AI) is transforming the world at a breakneck speed, with no sector insulated from its potency.

AstraZeneca is the latest pharma company enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with ...

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured ...

The FDA plans to "unleash AI" on new drug evaluations in order to "radically increase efficiency in the review process." ...

AstraZeneca (AZN) on Friday announced a strategic research collaboration with China-based CSPC Pharmaceuticals Group to ...

AstraZeneca has signed a deal worth up to $5.2bn to work with a Chinese biotech company using AI to develop new treatments for chronic diseases.

The company focuses on specialty drugs and uses a combination of AI and human expertise to automate the process.

AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, ...

Baron Funds, an investment management company, released its “Baron Asset Fund” first quarter 2025 investor letter. A copy of ...

During the first quarter of 2025, the Harbor Dividend Growth Leaders ETF returned –4.27%, underperforming the ETF’s style ...